$14.09
0.98% yesterday
NYSE, Dec 24, 09:30 pm CET
ISIN
US2561352038
Symbol
RDY

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock price

$14.09
+0.43 3.15% 1M
-1.50 9.62% 6M
-1.70 10.77% YTD
-1.58 10.08% 1Y
+3.57 33.99% 3Y
+0.00 0.03% 5Y
+4.97 54.50% 10Y
+11.95 559.03% 20Y
NYSE, Closing price Wed, Dec 24 2025
-0.14 0.98%
ISIN
US2561352038
Symbol
RDY
Industry

Key metrics

Basic
Market capitalization
$11.9b
Enterprise Value
$11.7b
Net debt
positive
Cash
$823.4m
Shares outstanding
832.5m
Valuation (TTM | estimate)
P/E
18.3 | 19.9
P/S
3.1 | 3.1
EV/Sales
3.1 | 3.1
EV/FCF
57.1
P/B
3.0
Dividends
DPS
$0.09
Yield 1Y | 5Y
0.7% | 0.6%
Growth 1Y | 5Y
-3.9% | 6.5%
Payout 1Y | 3Y
12.7% | 12.8%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$3.8b | $3.8b
EBITDA
$961.7m | $931.7m
EBIT
$749.4m | $712.3m
Net Income
$642.6m | $589.6m
Free Cash Flow
$205.6m
Growth (TTM | estimate)
Revenue
14.0% | 5.8%
EBITDA
6.0% | -4.0%
EBIT
1.5% | -8.8%
Net Income
8.1% | -6.3%
Free Cash Flow
119.6%
Margin (TTM | estimate)
Gross
66.9%
EBITDA
25.2% | 24.2%
EBIT
19.6%
Net
16.8% | 15.3%
Free Cash Flow
5.4%
Financial Health
Equity Ratio
67.9%
Return on Equity
16.9%
ROCE
17.1%
ROIC
14.0%
Debt/Equity
0.2
More
EPS
$0.8
FCF per Share
$0.2
Short interest
2.2%
Employees
27k
Rev per Employee
$130.0k
Show more

Is Dr. Reddy's Laboratories Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

45 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

13x Buy
29%
14x Hold
31%
18x Sell
40%

Analyst Opinions

45 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

Buy
29%
Hold
31%
Sell
40%

Financial data from Dr. Reddy's Laboratories Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,819 3,819
14% 14%
100%
- Direct Costs 1,265 1,265
29% 29%
33%
2,554 2,554
8% 8%
67%
- Selling and Administrative Expenses 878 878
40% 40%
23%
- Research and Development Expense - -
-
-
962 962
6% 6%
25%
- Depreciation and Amortization 212 212
26% 26%
6%
EBIT (Operating Income) EBIT 749 749
2% 2%
20%
Net Profit 643 643
8% 8%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Dr. Reddy's Laboratories Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock News

Neutral
Business Wire
23 days ago
BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
Positive
Seeking Alpha
about 2 months ago
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, with North America lagging but Europe and emerging markets offsetting declines through acquisitions and new launches. Key growth drivers include upcoming biosimilar Abatacept and generic GLP-1 drugs, ...
Neutral
Seeking Alpha
2 months ago
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC...
More Dr. Reddy's Laboratories Ltd. Sponsored ADR News

Company Profile

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Head office India
CEO Mr. Israeli
Employees 27,048
Founded 1984
Website www.drreddys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today